On October 29th, it was announced by sino biopharm that the company's Class 1 new drug BCL-2 inhibitor, TQB3909 tablet, has obtained approval for clinical trials from the National Medical Products Administration's Drug Evaluation Center (CDE), intended for use in combination with chemotherapy for the treatment of acute lymphocytic leukemia (ALL) patients.
中国生物制药1类新药BCL-2抑制剂获批临床
Sino biopharm Class 1 new drug BCL-2 inhibitor approved for clinical use.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated